Researchers at the University of Cambridge and Cambridge University Hospital NHS Foundation Trust have identified biological ‘fingerprints’ in the blood that can be used to potentially detect Covid-19, even several months after asymptomatic or mild infection. The findings can allow the development of a test to diagnose long Covid. This project, which is supported by the National Institute for Health Research funding, will use similar biological signatures to create another diagnostic test to complement current antibody tests for the disease.
Todos Medical has signed a distribution agreement with Fosun Pharma to launch its cPass SARS-CoV-2 Neutralizing Antibody Detection Kit, which is authorised by the US Food and Drug Administration under Emergency Use Authorization (EUA) to identify SARS-CoV-2 neutralising antibodies. Currently, the test is being automated to enable high-capacity testing and quick turnaround times. Todos will provide cPass as a testing service through its Provista Diagnostics laboratory as well as supply kits to client labs.
Quidel has collaborated with the state of Delaware, US, to deploy a full-service Covid-19 testing programme at schools via its new service provider, Quidel Services. The company will use its rapid antigen tests to screen students and faculty who opt-in to the initiative. Additionally, Quidel will staff test sites, manage sample collection, run the tests and report results to the Delaware Division of Public Health and the participating schools and school districts to facilitate screening for asymptomatic Covid-19 cases.